Eric Joseph
Stock Analyst at JP Morgan
(2.44)
# 1,168
Out of 4,655 analysts
120
Total ratings
50.65%
Success rate
-1.79%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Overweight | $54 → $63 | $55.13 | +14.28% | 5 | Nov 7, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $23 | $8.12 | +183.25% | 1 | Nov 5, 2024 | |
| WVE Wave Life Sciences | Maintains: Overweight | $13 → $17 | $13.67 | +24.36% | 2 | Oct 17, 2024 | |
| IGMS IGM Biosciences | Downgrades: Underweight | $12 → $9 | $9.47 | -4.96% | 7 | Oct 1, 2024 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $23 → $21 | $5.11 | +311.36% | 5 | Sep 10, 2024 | |
| BLUE bluebird bio | Downgrades: Neutral | n/a | $0.32 | - | 2 | Aug 15, 2024 | |
| NVAX Novavax | Maintains: Underweight | $8 → $9 | $7.32 | +22.95% | 7 | Aug 12, 2024 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $45 → $48 | $24.05 | +99.58% | 3 | Aug 7, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Underweight | $11 → $10 | $9.53 | +4.93% | 4 | Aug 6, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $50 → $54 | $13.98 | +286.27% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $34 | $22.92 | +48.34% | 6 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.83 | - | 4 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 | $39.23 | +35.10% | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $3.35 | +348.43% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $12 | $8.01 | +49.81% | 4 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $6.53 | +129.71% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $29.54 | -15.37% | 3 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $34 → $47 | $41.96 | +12.01% | 2 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $4.31 | +39.21% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $6.18 | +61.94% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $7.74 | +42.12% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $28.09 | +45.96% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $5 | $1.10 | +354.55% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $1.22 | +309.84% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $48 | $12.43 | +286.16% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.22 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $6.17 | +78.28% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.01 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $0.81 | +882.80% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $19.17 | +1,464.95% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.75 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $4.79 | +943.84% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $11 | $1.05 | +947.62% | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $3.08 | +192.21% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.79 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.62 | +1,503.05% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $4.21 | +208.79% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $2.05 | +436.59% | 3 | Nov 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.64 | - | 3 | Mar 2, 2018 |
Revolution Medicines
Nov 7, 2024
Maintains: Overweight
Price Target: $54 → $63
Current: $55.13
Upside: +14.28%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $8.12
Upside: +183.25%
Wave Life Sciences
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $13.67
Upside: +24.36%
IGM Biosciences
Oct 1, 2024
Downgrades: Underweight
Price Target: $12 → $9
Current: $9.47
Upside: -4.96%
Relay Therapeutics
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $5.11
Upside: +311.36%
bluebird bio
Aug 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.32
Upside: -
Novavax
Aug 12, 2024
Maintains: Underweight
Price Target: $8 → $9
Current: $7.32
Upside: +22.95%
Beam Therapeutics
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $24.05
Upside: +99.58%
Enanta Pharmaceuticals
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $9.53
Upside: +4.93%
Rocket Pharmaceuticals
Aug 6, 2024
Maintains: Overweight
Price Target: $50 → $54
Current: $13.98
Upside: +286.27%
Jul 15, 2024
Maintains: Overweight
Price Target: $31 → $34
Current: $22.92
Upside: +48.34%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.83
Upside: -
Jun 20, 2024
Maintains: Overweight
Price Target: $53
Current: $39.23
Upside: +35.10%
May 13, 2024
Maintains: Overweight
Price Target: $16 → $15
Current: $3.35
Upside: +348.43%
May 3, 2024
Maintains: Neutral
Price Target: $10 → $12
Current: $8.01
Upside: +49.81%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $6.53
Upside: +129.71%
Apr 18, 2024
Reiterates: Overweight
Price Target: $25
Current: $29.54
Upside: -15.37%
Feb 23, 2024
Maintains: Overweight
Price Target: $34 → $47
Current: $41.96
Upside: +12.01%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $4.31
Upside: +39.21%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $6.18
Upside: +61.94%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $7.74
Upside: +42.12%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $28.09
Upside: +45.96%
Aug 28, 2023
Downgrades: Neutral
Price Target: $15 → $5
Current: $1.10
Upside: +354.55%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $1.22
Upside: +309.84%
Aug 10, 2023
Maintains: Overweight
Price Target: $47 → $48
Current: $12.43
Upside: +286.16%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.22
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $6.17
Upside: +78.28%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $9.01
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $8
Current: $0.81
Upside: +882.80%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $19.17
Upside: +1,464.95%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $6.75
Upside: -
Jul 12, 2021
Initiates: Neutral
Price Target: $50
Current: $4.79
Upside: +943.84%
Apr 26, 2021
Initiates: Underweight
Price Target: $11
Current: $1.05
Upside: +947.62%
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $3.08
Upside: +192.21%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.79
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.62
Upside: +1,503.05%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $4.21
Upside: +208.79%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $2.05
Upside: +436.59%
Mar 2, 2018
Downgrades: Underweight
Price Target: n/a
Current: $1.64
Upside: -